Acute rejection and the therapeutic choice of drug.
Ichikawa
Y
Y
Department of Urology, Kidney Transplant Center and Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan.
Nojima
M
M
Kyo
M
M
Yazawa
K
K
Hanafusa
T
T
Ebisui
C
C
Tsubakihara
Y
Y
Fukunishi
T
T
Nagano
S
S
D000208:Acute Disease; D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy*; D006085:Graft Survival / Q000276:immunology*; D006146:Guanidines / Q000627:therapeutic use; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D006146:Guanidines; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; C037258:gusperimus; D016559:Tacrolimus